Efficacy and safety of atogepant for migraine prevention: a systematic review and meta-analysis of randomized controlled trials
Abstract
Background: Migraine is one of the most common neurological disorders, with an estimated prevalence of 15% of the population, affecting more than one billion people worldwide. Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist that was approved in 2021 by the US Food and Drug Administration for the preventive treatment of episodic migraine. However, its efficacy and safety are still uncertain. Objective: We performed a systematic review and meta-analysis to evaluate the efficacy and safety of atogepant for the preventive treatment of migraine. Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Web of Science from inception to June 2024 using “Atogepant”, “MK-8031”, “AGN-241689” and “migraine” search terms. Eligible articles were randomized clinical trials that showed efficacy and safety outcomes, such as changes from baseline in monthly migraine days and the incidence of adverse events (AEs), in patients who underwent migraine prevention with atogepant or placebo. Two independent reviewers extracted the data. Mean difference (MD) and risk ratio (RR) with 95% confidence intervals (95% CIs) were estimated. Results: Four studies were eligible for inclusion. The statistical analysis focused on the once-daily 60 mg dose of atogepant, as this dosage was the only one evaluated by at least three studies. In the patients who received atogepant, there was a significant decrease in monthly migraine days (MD…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.